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Abstract
Background: Starting HAART in a very advanced stage of disease is assumed to be the most prevalent form of initiation in
HIV-infected subjects in developing countries. Data from Latin America and the Caribbean is still lacking. Our main objective
was to determine the frequency, risk factors and trends in time for being late HAART initiator (LHI) in this region.
Methodology: Cross-sectional analysis from 9817 HIV-infected treatment-naı ¨ve patients initiating HAART at 6 sites
(Argentina, Chile, Haiti, Honduras, Peru and Mexico) from October 1999 to July 2010. LHI had CD4
+ count #200cells/mm
3
prior to HAART. Late testers (LT) were those LHI who initiated HAART within 6 months of HIV diagnosis. Late presenters (LP)
initiated after 6 months of diagnosis. Prevalence, risk factors and trends over time were analyzed.
Principal Findings: Among subjects starting HAART (n=9817) who had baseline CD4
+ available (n=8515), 76% were LHI:
Argentina (56%[95%CI:52–59]), Chile (80%[95%CI:77–82]), Haiti (76%[95%CI:74–77]), Honduras (91%[95%CI:87–94]), Mexico
(79%[95%CI:75–83]), Peru (86%[95%CI:84–88]). The proportion of LHI statistically changed over time (except in Honduras)
(p#0.02; Honduras p=0.7), with a tendency towards lower rates in recent years. Males had increased risk of LHI in Chile,
Haiti, Peru, and in the combined site analyses (CSA). Older patients were more likely LHI in Argentina and Peru (OR 1.21 per
+10-year of age, 95%CI:1.02–1.45; OR 1.20, 95%CI:1.02–1.43; respectively), but not in CSA (OR 1.07, 95%CI:0.94–1.21). Higher
education was associated with decreased risk for LHI in Chile (OR 0.92 per +1-year of education, 95%CI:0.87–0.98) (similar
trends in Mexico, Peru, and CSA). LHI with date of HIV-diagnosis available, 55% were LT and 45% LP.
Conclusion: LHI was highly prevalent in CCASAnet sites, mostly due to LT; the main risk factors associated were being male
and older age. Earlier HIV-diagnosis and earlier treatment initiation are needed to maximize benefits from HAART in the
region.
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Introduction
Since the introduction of highly active antiretroviral therapy
(HAART) for the treatment of HIV infection, the benefits in
survival have been clearly established [1]. The stage of HIV
infection at the time of HAART initiation plays an important role
in patients’ prognosis after treatment. Patients with advanced
disease when starting HAART are less likely to achieve virological
suppression, more likely to modify their therapy due to adverse
events, have a higher mortality rate and represent a financial strain
in public health services, as compared with those who initiate
earlier [2–11]. Therefore, in recent years there has been a push
towards earlier initiation of HAART to improve survival and
decrease AIDS complications [12–15]. Furthermore, earlier
HAART initiation may result in a lower risk of HIV transmission,
as suppressing HIV-1 RNA levels has been shown to diminish
transmission rates [16,17]. As a result, early diagnosis and
treatment of HIV constitutes a major public health issue.
Despite efforts to improve the care of people living with HIV, a
considerable proportion of subjects do not obtain medical
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[8,18–19]. Several studies conducted in high income countries in
the past decade found that 20% to 40% of patients diagnosed with
HIV were in advanced disease stages (in most studies defined as
presenting with CD4 cell counts less than 200 cells/mm
3 and/or a
history of an AIDS-defining illness). Consequently, these patients
were late HAART initiators [20]. Late HAART initiation can be
attributed to late HIV diagnosis due to late testing (LT), or to late
presentation (LP) to care after diagnosis has been established.
Although late testing and late presentation may have similar
consequences for the prognosis of individual patients when starting
HAART [4–6], differences between LT and LP may reflect
failures at different steps of health care access [21]. In Latin
America and the Caribbean, studies show high frequencies of late
stage of disease at HAART initiation [9–10,22–23]. However, risk
factors associated with LHI have not been well described. The
aims of this study were to evaluate the proportion of patients who
were LHI between the years of 2000 and 2010, to assess trends
across the study period, to look for risk factors associated with
LHI, and to determine if LHI was due to late diagnosis or late
presentation using data from the Caribbean, Central and South
American network for HIV Research (CCASAnet) [24].
Methods
The CCASAnet cohort (http://ccasanet.vanderbilt.edu/) has
been described elsewhere [9–10,24]. The collaboration was
established in 2006 as Region 2 of the International Epidemiologic
Databases to Evaluate AIDS (IeDEA; www.iedea-hiv.org) with the
purpose of collecting HIV data from Central and South America
and the Caribbean to be able to describe the unique characteristics
of the HIV epidemic in this region. Six CCASAnet sites
contributed data to this study: Fundacio ´n Hue ´sped in Buenos
Aires, Argentina (FH-Argentina); Fundacio ´n Arriara ´n in Santiago,
Chile (FA-Chile); Le Groupe Haı ¨tien d’Etude du Sarcome de
Kaposi et des Infections Opportunistes in Port-au-Prince, Haiti
(GHESKIO-Haiti); Instituto Honduren ˜o de Seguridad Social and
Hospital de Especialidades in Tegucigalpa, Honduras (IHSS/HE-
Honduras); El Instituto Nacional de Ciencias Me ´dicas y Nutricio ´n
Salvador Zubira ´n in Mexico City, Mexico (INNSZ-Mexico); and
El Instituto de Medicina Tropical Alexander von Humboldt in
Lima, Peru ´ (IMTAvH-Peru). Institutional review board approval
was obtained locally for each participating site and for the
CCASAnet data coordinating center (DCC) at Vanderbilt
University, Nashville, TN, USA.
Study design and population
The source population for this cross-sectional analysis was HIV-
infected adults receiving medical care at the 6 participating
CCASAnet sites. Treatment-naı ¨ve patients who started HAART
between October 1999 and July 2010 were included. HAART was
defined in all sites as all regimens with at least 3 antiretroviral
drugs (mainly composed with 2 nucleoside/nucleotide analogs of
reverse transcriptase inhibitors plus a no-nucleoside/nucleotide
analogs of reverse transcriptase inhibitors or a protease inhibitor).
All participant sites are part of local programs for universal free
access to HAART. Late HAART initiators (LHI) were defined as
those subjects with a non-missing baseline CD4 cell count (6
months before or 1 week after starting HAART) who either had
baseline CD4#200 cell/mm
3 or an AIDS-defining illness (ADI)
prior to or at HAART initiation. LHI were further classified as
either late testers (LT) or late presenters (LP), corresponding to
those who started HAART within 6 months of HIV diagnosis (LT)
or more than 6 months after HIV diagnosis (LP). The remaining
patients were considered non-late HAART initiators (NLHI). All
study definitions were chosen a priori.
Data Collection
Each participant site contributed data from their database using a
standard data transfer protocol. Demographic, clinical, and
laboratory data for all sites were prospectively collected and
periodically recorded. The databases are updated routinely and
sent to the DCC. Data were checked for errors and inconsistencies.
We collected data on sex, age at HAART initiation, probable
route of infection (self-reported as sexual – either homosexual or
heterosexual intercourse – or non-sexual), marital status (only
available in GHESKIO-Haiti, INNSZ-Mexico and IMTAvH-
Peru), employment status (employed/unemployed), and years of
education at first clinic visit. In sites with available data (FH-
Argentina and INNSZ-Mexico), sexual probable route of infection
was further classified as homosexual or heterosexual. Baseline
CD4 cell count was defined as the measurement closest to
HAART initiation but not more than 6 months prior to, or 7 days
after, the date of HAART start. Values not available within this
time frame were considered missing.
Statistical Analysis
Trends in the proportion of LHI across the study period were
assessed non-parametrically using Friedman’s ‘super smoother’ [25].
The association between LHI and risk factors was evaluated using
univariate and multivariate logistic regression models. The primary
multivariate analysis included age, sex, years of education, and date
of HAART initiation – variables which were measured in all sites.
Age and years of education were included as continuous variables.
Secondary, site-specific multivariate models also included probable
route of infection, marital status, and employment status, when
available. Date of HAART initiation was included in the models
using restricted cubic splines to account for non-linear time-trends
[26]. Combined-site estimates were computed using random effects
methods [27,28]. Risk factors for LT and LP were assessed using
multinomial logistic regression. In primary analyses, patients missing
baseline CD4 cell count (LHI analyses) and baseline CD4 cell count
or date of HIV diagnosis (LT/LP analyses) were excluded. Analyses
were repeated incorporating data from all patients using multiple
imputation techniques [29]. Statistical analyses were performed
using STATA version 10 and R version 2.11.1.
Results
A total of 9817 subjects started HAART during the study
period. Patient characteristics stratified by site and combined are
shown in Table 1 and Table S1 (Supporting Information section).
The median age at HAART initiation was 36 years (interquartile
range 30–43); 40% of patients were female, ranging from 55% in
GHESKIO-Haiti to 11% in FA-Chile. The probable route of HIV
infection was sexual for the majority of patients; only FH-
Argentina had a substantial portion of patients whose probable
route of infection was non-sexual. The mean years of education at
first clinic visit was 8.6 (Standard Deviation 4.9) ranging from 6.1
years in GHESKIO-Haiti to 13.1 in FA-Chile. Twenty percent of
patients were married, although marital status was only available
in GHESKIO-Haiti, IHSS/HE-Honduras, INNSZ-Mexico and
IMTAvH-Peru. Employment status at entrance to care was
available in all sites except GHESKIO-Haiti; 73% of the cohort
was employed. The median CD4 cell count at HAART initiation
was 129 cells/mm
3 (IQR 49–219); baseline CD4 cell count was
missing for 1302 subjects (13%). The median time between HIV
diagnosis and HAART initiation was 153 days (5.1 months; IQR
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subjects. The time period of the study differed between sites,
although all sites contributed data from 2003–2008.
Rates of LHI
Of 8515 patients with a recorded baseline CD4 cell count,
6431 (76% [95%CI: 74–77]) were LHI: 56% [95%CI: 52–59] in
FH-Argentina, 80% [95%CI: 77–82] in FA-Chile, 76% [95%CI:
74–77] in GHESKIO-Haiti, 91%[95%CI: 87–94] in IHSS/HE-
Honduras, 79% [95%CI: 75–83]) in INNSZ-Mexico and 86%
[95%CI: 84–88] in IMTAvH-Peru. At HAART initiation,
70.4% of patients had CD4,200 (with or without ADI),
30.5% had an ADI (regardless of CD4+ count), and 25.6%
had both characteristics. The proportion of LHI over time for
each site is shown in Figure 1. For all of the sites except IHSS/
HE-Honduras, the proportion of LHI statistically changed over
time (p,0.001 for FH-Argentina, FA-Chile, GHESKIO-Haiti,
and IMTAvH-Peru; p=0.02 for INNSZ-Mexico; and p=0.86
for IHSS/HE-Honduras). Rates of LHI tended to be lower in
more recent years for most of the sites. The rates of LHI in
INNSZ-Mexico and GHESKIO-Haiti increased in earlier years
followed by a decrease in later years. In contrast, in FH-
Argentina the rate of LHI decreased in earlier years and stayed
roughly constant from 2004 to 2009. Note that 95.2% of patients
started HAART with CD4,350 or an ADI.
Risk factors for LHI
In multivariate logistic analyses including age, sex, years of
education, and date of HAART initiation, male sex was associated
with an increased risk of LHI in FA-Chile, GHESKIO-Haiti,
IMTAvH-Peru, and in the combined site analyses (OR=2.93, 95%
CI 1.59–5.40; OR=1.27, CI 1.06–1.51; OR=2.28, CI 1.64–3.18;
OR=1.69, CI 1.24–2.30; respectively; Table 2). Older patients
were more likely to be LHI in FH-Argentina and IMTAvH-Peru
(OR 1.21 per 10 year increase in age, 95% CI 1.02–1.45; OR 1.20,
CI 1.02–1.43; respectively), although this trend was not seen across
all cohorts (OR 1.07, 95% CI 0.94–1.21). Higher education was
statistically associated with a decreased risk of LHI in FA-Chile (OR
0.92 per additional year of education, CI 0.87–0.98), and similar
trends, although not statistically significant, were seen in INNSZ-
Mexico, IMTAvH-Peru, and in the combined site analysis. The
estimated probability of LHI over time after adjusting for age, sex,
and education was similar to the unadjusted trends seen above,
except perhaps in FH-Argentina where there appeared to be a
stronger recent trend to lower rates of LHI (see Figure S1 of
Supporting Information section).
Table 1. Patient characteristics at time of HAART initiation by site.
FH-Argentina FA-Chile GHESKIO-Haiti
IHSS/HE-
Honduras INNSZ-Me ´xico IMTAvH-Peru ´ Combined
N=1642 N=931 N=4458 N=575 N=557 N=1654 N=9817
Age
a 35(30–41) 37(31–43) 37(30–44) 36(30–42) 34(28–41) 34(28–42) 36(30–43)
% missing
b 4.5 1.5 19.5 0 0 0 9.7
Female n(%) 501(30) 106(11) 2477(55) 274(48) 65(12) 485(29) 3908(40)
Sexual transmission
n(%)
c
1224(85) 912(99) - 550(99) 538(98) 1302(99) 8916(97)
% missing 11.8 1.5 100 4 1.9 20.8 51.4
Married n(%) - - 743 (17) 43(54) 88(16) 544(36) 1418(22)
% missing 100 100 0.7 86.3 2.7 9.8 33.4
Education years
d 10.44(4.9) 13.06(3.5) 6.10(4.4) 7.56(3.9) 11.73(4.1) 11.74(2.6) 8.55(4.9)
% missing 47.7 1.5 19.5 0 0 0 14.4
Employed n(%) 786(74) 561(65) - 338(79) 348(63) 1179(78) 3212(73)
% missing 34.9 7.6 100 25.4 0.3 8.6 54.9
CD4 count
a 181(56–309) 140 (51–210) 133 (55–207) 105 (53–185) 147 (54–254) 82 (32–176) 129 (49–219)
% missing 19.7 0 8.6 33.4 14.0 19.4 13.3
LHI n(%) 734(55.7) 742(79.7) 3086(75.8) 347(90.6) 379(79.1) 1143(85.7) 6431(75.5)
% missing 19.7 0 8,6 33.4 14.0 19.4 13.3
CD4,200 & no
ADI n(%)
607(46.0) 393(42.2) 2211(54.3) 88(22.9) 121(25.3) 412(30.9) 3832(45)
ADI & CD4.200 n(%) 21(1.6) 90(9.7) 101(2.5) 43(11.2) 79(16.5) 80(6.0) 414(4.9)
CD4,200 & ADI n(%) 106(8.0) 259(27.8) 774(19.0) 216(56.4) 179(37.4) 651(48.8) 2185(25.7)
NOTE. HAART, highly active antiretroviral therapy; FH-Argentina, Fundacio ´n Hue ´sped in Buenos Aires; FA-Chile, Fundacio ´n Arriara ´n in Santiago, GHESKIO-Haiti, Le
Groupe Haı ¨tien d’Etude du Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince; IHSS/HE-Honduras Instituto Honduren ˜o de Seguridad Social and
Hospital de Especialidades in Tegucigalpa; INNSZ-Mexico, Instituto Nacional de Ciencias Me ´dicas y Nutricio ´n Salvador Zubira ´n in Mexico City; and IMTAvH-Peru, Instituto
de Medicina Tropical Alexander von Humboldt in Lima; LHI, late HAART initiators.
aMedian (interquartile range) reported for all continuous variables except education years.
bMissing values correspond to variables not routinely collected by some sites (e.g. marital status) or values not available within the required time frame (e.g. baseline
CD4).
cInformation about MSM transmission was only available in Argentina and Mexico. Argentina had 437 MSM (35.9%) and Mexico 312 MSM (65.1%).
dMean (standard deviation) reported for education years.
doi:10.1371/journal.pone.0020272.t001
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which were recorded at specific sites, employment was associated
with lower rates of LHI in FH-Argentina (OR 0.50, 95% CI 0.27–
0.92), but not in FA-Chile, IHSS/HE-Honduras, INNSZ-Mexico,
or IMTAvH-Peru (p.0.1 for all) (see Table S2 of Supporting
Information section). In FH-Argentina, men who have sex with men
(MSM) and those whose probable route of infection was
heterosexual tended to have lower rates of LHI than those whose
probable route of infection was non-sexual (OR=0.49, 95% CI
0.24–1.00; OR=0.66, 95% CI 0.32–1.35; respectively); in INNSZ-
Mexico, MSM also tended to have lower rates of LHI than
heterosexuals, although this was not statistically significant
(OR=0.81, 95% CI 0.41–1.58). Being married had little association
with LHI in any of the sites that recorded marital status (OR 0.92,
95% CI 0.73–1.16, p=0.48; OR 0.58, 95% CI 0.29–1.17, p=0.13;
OR 0.76, 95% CI 0.53–1.07, p=0.11 for GHESKIO-Haiti,
INNSZ-Mexico, and IMTAvH-Peru, respectively).
Rates of LT and LP
Of 6047 LHI with a recorded date of HIV diagnosis, 3331
(55%) were late testers and 2716 (45%) were late presenters,
corresponding to 42% and 34% of the 7901 patients in the overall
cohort with complete data. The proportion of late HAART
initiators who were LT was 50% for FH-Argentina, 23% for FA-
Chile, 63% for GHESKIO-Haiti, 56% for IHSS/HE-Honduras,
48% for INNSZ-Mexico, and 59% for IMTAvH-Peru. Temporal
Figure 1. Temporal trends in the proportion of patients classified as late HAART initiators. NOTE. FH-Argentina, Fundacio ´n Hue ´sped in
Buenos Aires, Argentina; FA-Chile, Fundacio ´n Arriara ´n in Santiago, Chile; GHESKIO-Haiti, Le Groupe Haı ¨tien d’Etude du Sarcome de Kaposi et des
Infections Opportunistes in Port-au-Prince, Haiti; IHSS/HE-Honduras Instituto Honduren ˜o de Seguridad Social and Hospital de Especialidades in
Tegucigalpa, Honduras; INNSZ-Mexico, El Instituto Nacional de Ciencias Me ´dicas y Nutricio ´n Salvador Zubira ´n in Mexico City, Mexico; and IMTAvH-
Peru, El Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru ´.
doi:10.1371/journal.pone.0020272.g001
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late testers and late presenters both dropped substantially in
GHESKIO-Haiti in recent years, although in 2007–2008 over
60% of GHESKIO-Haiti’s LHI were late testers.
Risk Factors for LT and LP
Male sex was associated with late presentation and especially
late testing for most sites and when all sites were considered
together (Table 3; combined OR=1.51, 95% CI 1.12–2.03, p-
value 0.001 for LP; combined OR=1.76, 95% CI 1.36–2.29, p-
value,0.001 for LT). Older age was a risk factor for late testing
(OR=1.17 per 10 year increase in age, 95% CI 1.03–1.34, p-
value 0.02), whereas higher education tended to be associated with
a decreased risk of late presentation (OR 0.97, 95% CI 0.95–1.00,
p-value 0.005).
Analyses were repeated using multiple imputation techniques
to include patients with incomplete data. In general, results were
very similar to those reported above (Supporting Information
section). The estimated rates of LHI were 56% in FH-Argentina,
80% in FA-Chile, 76% in GHESKIO-Haiti, 89% in IHSS/HE-
Honduras, 78% in INNSZ-Mexico, and 86% in IMTAvH-Peru.
The only notable changes in multivariate analyses were 1)
education was associated with LHI in FH-Argentina (OR=0.97
per year, 95% CI 0.95–0.99) and 2) the association between age
and LHI in IMTAvH-Peru slightly weakened (OR=1.16 per 10
years, 95% CI 0.98–1.37).
Table 2. Multivariate analyses of factors associated with late HAART initiation
a.
FH-Argentina FA-Chile GHESKIO-Haiti IHSS/HE-HondurasINNSZ-Me ´xico IMTAvH-Peru ´ Combined
Age 1.21 0.93 0.95 0.86 1.22 1.20 1.07
(per 10 yrs) (1.02, 1.45) (0.76, 1.14) (0.87, 1.04) (0.56, 1.32) (0.94, 1.59) (1.02, 1.43) (0.94, 1.21)
p-value 0.03 0.49 0.30 0.49 0.13 0.03 0.31
Male 1.19 2.93 1.27 1.59 1.91 2.28 1.69
(0.83, 1.69) (1.59, 5.40) (1.06, 1.51) (0.68, 3.72) (0.93, 3.92) (1.64, 3.18) (1.24, 2.30)
p-value 0.34 ,0.001 0.01 0.28 0.08 ,0.001 0.001
Education 0.99 0.92 0.99 0.98 0.95 0.94 0.97
(per 1 yr) (0.95, 1.02) (0.87, 0.98) (0.97, 1.01) (0.88, 1.08) (0.90, 1.02) (0.88, 1.01) (0.95, 1.00)
p-value 0.46 0.008 0.48 0.66 0.14 0.07 0.02
NOTE. HAART, highly active antiretroviral therapy; FH-Argentina, Fundacio ´n Hue ´sped in Buenos Aires, Argentina; FA-Chile, Fundacio ´n Arriara ´n in Santiago, Chile;
GHESKIO-Haiti, Le Groupe Haı ¨tien d’Etude du Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince, Haiti; IHSS/HE-Honduras Instituto Honduren ˜od e
Seguridad Social and Hospital de Especialidades in Tegucigalpa, Honduras; INNSZ-Me ´xico, El Instituto Nacional de Ciencias Me ´dicas y Nutricio ´n Salvador Zubira ´ni n
Mexico City, Mexico; and IMTAvH-Peru ´, El Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru ´.
aData shown are odds ratios (95% confidence intervals). Estimates are adjusted for all variables in the table as well as date of HAART initiation using a logistic regression
model.
doi:10.1371/journal.pone.0020272.t002
Figure 2. Temporal trends in the proportion of patients classified as late testers and late presenters. NOTE. The left and center plots
are the corresponding proportions based on the entire cohort population (denominator=all HAART initiators). The right plot shows trends in the
proportion of late HAART initiators who were late testers (denominator=all late HAART initiators). Rates of LT (left plot) statistically changed over
time for most sites (p,0.001 for all sites except FH-Argentina where p=0.42). Rates of LP (center plot) also changed over time for most sites (p=0.11,
0.007, ,0.001, 0.01, ,0.001, and 0.01 for FH-Argentina, FA-Chile, GHESKIO-Haiti, IHSS/HE-Honduras, INNSZ-Mexico, and IMTAvH-Peru, respectively).
FH-Argentina, Fundacio ´n Hue ´sped in Buenos Aires, Argentina; FA-Chile, Fundacio ´n Arriara ´n in Santiago, Chile; GHESKIO-Haiti, Le Groupe Haı ¨tien
d’Etude du Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince, Haiti; IHSS/HE-Honduras Instituto Honduren ˜o de Seguridad Social
and Hospital de Especialidades in Tegucigalpa, Honduras; INNSZ-Mexico, El Instituto Nacional de Ciencias Me ´dicas y Nutricio ´n Salvador Zubira ´ni n
Mexico City, Mexico; and IMTAvH-Peru, El Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru ´. LHI, late HAART initators.
doi:10.1371/journal.pone.0020272.g002
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The present study conducted among cohorts in different sites
from 6 Latin-American countries shows that a significant
proportion of patients starting HAART in this region do so after
they have experienced an AIDS-defining illness or when the CD4
cell count is lower than 200, far below the cutoff of 350 cells/mm
3
that is the recommended by most of the current international
guidelines [30–32]. The prevalence of late HAART initiation as
defined in this study ranges from 56% in FH-Argentina to 91% in
IHSS/HE-Honduras with a combined mean of 75%. This finding
presents a harsh reality to the current debate on when to start
antiretroviral treatment [33,34]. While recent World Health
Organization guidelines [30] have raised the target CD4 cell
count at which treatment should be initiated, we found that most
patients in our region still initiate treatment at a level which is far
from optimal. In contrast to previous studies [20], our study
analyzed not only the frequency with which patients present late to
care, but as importantly, the frequency at which patients initiate
therapy late. It has been assumed from previous studies that the
main reason for late HAART initiation is that patients are not
diagnosed early enough, often reflecting a failure of the local
health systems to implement widespread testing strategies [2,4,35].
In our study, however, a surprising finding was that a significant
proportion of LHI (nearly 50% in the combined cohort; the
proportion of patients who were LHI and were diagnosed more
than 6 months before HAART initiation ranged from as high as
80% in FA-Chile, to approximately 40% in GHESKIO-Haiti and
IMTAvH-Peru) were in fact diagnosed more than 6 months before
starting HAART, and therefore, initiating late was not necessarily
due to patients testing for HIV at late stages of disease but to other
unexplained reasons. These reasons could include a poor linkage
between the testing programs and the access to care facilities
[20,36,37], need to be further studied. The high rates of late
presentation are particularly noteworthy because access to
HAART should not be a problem in any of the participating
sites, as compared to other reports in Latin America [38], given
that each is part of local programs for universal coverage of
HAART paid by their respective governments.
Recently, in a large cohort of 14 sites in the USA and Canada
(NA-ACCORD), late presentation to care seem to be have been
decreasing between 1997 and 2007, based on the change in the
median of CD4+ count at presentation to care [39]. In our region,
from 2004 to 2009 there appears to be a trend towards fewer
patients initiating HAART in advanced disease stages in more
recent years. This was particularly apparent in Haiti, where rates
of LHI have substantially dropped since 2007. This drop is most
likely attributable to a clinic-wide effort to initiate HAART in
patients at earlier disease stages and also to the CIPRA study
conducted at GHESKIO, which included patients starting
HAART with CD4 cell counts that were higher than 200 cells/
mm
3 [15]. Furthermore, GHESKIO has an integrated testing and
treatment center, which facilitates linkages in care [15,40,41]. The
high rates of LHI in the earlier study years could be attributed in
part to local guidelines containing late thresholds for initiating
HAART [41–45]. Trends towards lower rates of LHI in recent
Table 3. Multivariate analyses of risk factors associated with late testers and late presenters
a.
FH-Argentina FA-Chile GHESKIO-Haiti
IHSS/HE-
Honduras INNSZ-Me ´xico IMTAvH-Peru ´ Combined
LT
Age (10 yr) 1.50 1.08 1.04 0.87 1.28 1.23 1.17
(1.20–1.88) (0.86–1.37) (0.94–1.14) (0.54–1.41) (0.95–1.72) (1.03–1.46) (1.03–1.34)
p-value 0.00 0.47 0.43 0.59 0.10 0.02 0.02
Male 1.44 1.95 1.36 2.23 2.57 2.32 1.76
(0.90–2.31) (1.03–3.67) (1.12–1.64) (0.89–5.6) (1.08–6.14) (1.63–3.30) (1.36–2.29)
p-value 0.12 0.04 0.001 0.08 0.03 0.00 0.00
Education (yr) 1.00 1.00 0.99 0.99 0.95 0.96 1.00
(0.96–1.05) (0.99–1.01) (0.97–1.02) (0.89–1.11) (0.88–1.01) (0.90–1.03) (1.00–1.01)
p-value 0.87 0.27 0.93 0.97 0.13 0.29 0.40
LP
Age (10 yr) 0.99 0.89 0.77 0.87 1.25 1.06 0.95
(0.78–1.26) (0.74–1.07) (0.69–0.86) (0.54–1.42) (0.94–1.67) (0.88–1.27) (0.81–1.11)
p-value 0.96 0.24 0.00 0.58 0.12 0.52 0.53
Male 1.18 2.19 1.12 1.30 1.53 2.12 1.51
(0.76–1.84) (1.33–3.63) (0.90–1.38) (0.52–3.26) (0.69–3.41) (1.46–3.07) (1.12–2.03)
p-value 0.46 0.002 0.30 0.57 0.29 0.00 0.001
Education (yr) 0.96 1.00 0.97 0.96 0.95 0.92 0.97
(0.92–1.01) (0.99–1.01) (0.95–1.00) (0.85–1.07) (0.89–1.02) (0.86–0.98) (0.95–1.00)
p-value 0.10 0.07 0.06 0.44 0.16 0.02 0.005
NOTE. FH-Argentina, Fundacio ´n Hue ´sped in Buenos Aires, Argentina; FA-Chile, Fundacio ´n Arriara ´n in Santiago, Chile; GHESKIO-Haiti, Le Groupe Haı ¨tien d’Etude du
Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince, Haiti; IHSS/HE-Honduras Instituto Honduren ˜o de Seguridad Social and Hospital de Especialidades
in Tegucigalpa, Honduras; INNSZ-Mexico, El Instituto Nacional de Ciencias Me ´dicas y Nutricio ´n Salvador Zubira ´n in Mexico City, Mexico; and IMTAvH-Peru, El Instituto de
Medicina Tropical Alexander von Humboldt in Lima, Peru ´.
aData shown are odds ratios (95% confidence intervals). Estimates are adjusted for all variables in the table as well as date of HAART initiation.
doi:10.1371/journal.pone.0020272.t003
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despite these trends, the prevalence of LHI in the most recent
years still remains unacceptably high.
The outstanding risk factor for LHI in the multivariate analysis
was male sex. Older age and less education were also associated
with higher rates of LHI in many of the sites. Even though the
AIDS epidemic in most of the participating countries is driven by
MSMs, in the sites where these data were available (INNSZ-
Mexico and FH-Argentina) MSMs tended to have a somewhat
lower risk of being LHI. In the combined analysis of all cohorts,
the same factors (male sex and older age) were significantly
associated with late testing (recent diagnosis in LHI) and with late
presentation (diagnosis more than 6 months before HAART
initiation). These risk factors are similar to those reported in other
studies for patients diagnosed in advanced stages [8].
One limitation of our study is the number of missing CD4 cell
counts at HAART initiation from some of the sites. The analysis
presented excluded those patients without data, which may bias
the results. However, we obtained similar results using multiple
imputation techniques which allow the inclusion of all patients
initiating HAART. Another potential limitation is that we may
have had insufficient power to detect some risk factors for LHI due
to there being very few NLHI in some sites. The heterogeneity
between rates of LHI at the different sites is also noteworthy, and
suggests that there are important differences between clinic
settings, perhaps in traditions, culture, HIV stigma, testing
services, education, or something else. Unfortunately, with only
six sites, we do not have sufficient data to investigate site-specific
factors associated with LHI.
It is important to emphasize that our study did not measure the
rate of late testing, but rather the proportion of patients who
started HAART who were considered late testers. Of course, these
patients represent only those who made it to care and received
treatment. Our study does not consider persons in late stages of
disease who do not know their HIV status, or diagnosed patients in
late stages of disease who have not started treatment.
In conclusion our study shows a high rate of HAART initiation
at CD4 cell counts ,200 cell/mm
3 or with an AIDS-defining
illness in Latin-American and the Caribbean, which is substan-
tially below the current cutoff recommended in international
guidelines [30–32]. This observation is mostly explained by late
HIV diagnosis however, a significant proportion of patients across
all sites that meet criteria for treatment initiation experience
considerable delays between the time of HIV diagnosis and the
initiation of HAART. Avoiding this delay by improving the
linkage between testing and treatment, as well as promoting early
diagnosis of HIV, should result in better immunologic status at
HAART initiation and better outcomes.
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